Seeing Machines' glaucoma technology shows success in phase 1 trial

By Lisa Kerner

Erie, Pa., Jan. 10 - Seeing Machines Ltd. said the first major clinical trial of its new technology for detection and management of glaucoma showed success. Glaucoma is the group of eye diseases that affect peripheral vision, often leading to permanent vision loss.

The phase 1 study demonstrated that the technology detects the loss of visual field associated with glaucoma, according to a company news release. The technology also proved able to differentiate between those patients with visual field loss and those without. The result, according to the company, provides the basis for a reliable and accurate diagnostic instrument.

"The technical progress demonstrated in this trial has assisted Seeing Machines in reaching a key milestone of our entire medical device development program," Seeing Machines chief executive officer Nick Cerneaz said in the release.

"The preparations for the next major clinical trial aimed at testing these developments are well underway with an anticipated start date this quarter. We are very excited about these results and keen to build further on them as we pursue our goal of delivering the world's first non-contact objective test for glaucoma."

Seeing Machines, with headquarters in Canberra, Australia, develops computer-based imaging software systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.